PI3K inhibitor (pan-class I)
Assets acting on this target.
Assets acting on this target.
3 of 3 assets (3 discontinued)
| Drug | Owner | Mechanism | Indication | Reached | Why it stopped | Source |
|---|---|---|---|---|---|---|
| Buparlisib | Novartis | PI3K inhibitor (pan-class I) | HR+/HER2- Metastatic Breast Cancer | Ph 3 | EfficacyNo active buparlisib/BKM120 trials in breast cancer were found beyond this candidate's own evidence trial (NCT02154776, from the BELLE-2/3 era); Novartis's pan-PI3K inhibitor program in breast cancer is publicly documented as discontinued following marginal efficacy and significant toxicity in Phase 3. | source ↗ |
| Buparlisib | Novartis | PI3K inhibitor (pan-class I) | Head and Neck Squamous Cell Carcinoma | Ph 3 | Company-directed Phase 3 disclosed in ANL 10-K (2026-04-16) | source ↗ |
| Buparlisib | Novartis | PI3K inhibitor (pan-class I) | Non-Small Cell Lung Cancer | Ph 2 | StrategicNovartis's PI3K inhibitor buparlisib (BKM120) was tested in NSCLC in the BASALT-1/BASALT-2 studies, but the BASALT-2 combination study (NCT01820325) was terminated due to a challenging safety profile, and Novartis subsequently made the decision not to pursue further development of buparlisib and terminated its ongoing studies across indications. | source ↗ |